Impact of a designated hepatology nurse on the clinical course and quality of life of patients treated with rebetron
therapy for chronic hepatitis C.
veterans' experience with rebetron
in a nonstudy environment: success or failure?
* Interferons such as Roferon-A, Intron-A, and Rebetron
, used to boost immune response
He successfully completed a course of rebetron
and ribavirin and was cleared for renal transplant.
Schering-Plough's United States alpha interferon products include INTRON A (interferon alfa-2b, recombinant) Injection; PEG-INTRON (peginterferon alfa-2b) Powder for Injection; and REBETRON
Combination Therapy containing REBETOL (ribavirin, USP) Capsules and INTRON A.
"These earnings reflect the successful launch of the new combination of PEG-Intron-Rebetol in the US and Europe and the launch of Rebetron
combination treatment in Japan by our partner, Schering-Plough," said Johnson Y.N.
The FDA encourages health care providers to report pregnancies in women on Rebetol or the sexual partners of men on Rebetol to the Rebetron
Pregnancy Registry at 800-727-7064.
Schering-Plough has reported it will continue to market REBETRON
Combination Therapy in the United States.
Fried, MD, of the University of North Carolina, Chapel Hill, and colleagues found a higher sustained viral response rate among HCV patients treated with this combination of drugs than with the current standard therapy, interferon alfa-2b plus ribavirin (Rebetron
), said a Medscape Wire article.
Hepatitis C has no cure and no vaccine to combat it, but a new product, Rebetron
, received FDA approval last June for the treatment of chronic hepatitis C in patients who have undergone a relapse following alpha interferon therapy.
Schering-Plough Corporation, Madison, NJ, announced the US Food and Drug Administration (FDA) has approved Rebetron
Combination Therapy containing Rebetol (ribavirin, USP) capsules and Intron A (interferon alfa-2b, recombinant) injection for the treatment of hepatitis C in patients with compensated liver disease previously untreated with alpha interferon therapy.
Ribavirin, a nucleoside analogue, is licensed to Schering-Plough (Kenilworth, NJ) and marketed in combination with Schering-Plough's interferon alfa-2b product (Rebetron
) and with pegylated interferon alfa-2b (PEG-Intron -- Rebetol) for the treatment of chronic hepatitis C.